Integral Molecular Retains Top Workplace Status in Philadelphia

Sharon Willis, co-founder of the firm, credits the repeat recognition to the company’s sustained focus on scientific collaboration and professional growth. The organization currently supports a workforce dedicated to complex drug discovery, specifically targeting membrane proteins and viral threats like SARS-CoV-2 and Ebola. By fostering an environment that prioritizes internal development alongside regional community partnerships, the company aims to retain local talent while scaling its research operations.

Since its inception, the company has integrated its proprietary technologies into the pipelines of over 600 pharmaceutical and biotech partners. This latest accolade arrives as the firm continues to expand its role within Pennsylvania’s life sciences sector, balancing its commitment to advancing therapeutic solutions for cancer and autoimmune disorders with a people-first management approach.